S-EPMC12296598 - Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome - OmicsDI

Unknown

Dataset Information

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome

ABSTRACT:

SUBMITTER: Eng W

PROVIDER: S-EPMC12296598 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature